Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mild hemophilia B is a form of hemophilia B characterized by a small deficiency of factor IX leading to abnormal bleeding as a result of minor injuries, or following surgery or tooth extraction.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for mild hemophilia B.
26 publications have been identified in PubMed for mild hemophilia B. Research spans Epidemiology / Natural History (35%), Basic Science / Preclinical (26%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 8 | 35% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:56 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
6 |
26% |
Patient case studies | 4 | 17% |
Research summaries | 2 | 9% |
Clinical study results | 2 | 9% |
Other research | 1 | 4% |
Singer H (2026). [PMID: 41307134](https://pubmed.ncbi.nlm.nih.gov/41307134/). *Haematologica*. [Basic Science / Preclinical]
Zhang H (2026). [PMID: 41508136](https://pubmed.ncbi.nlm.nih.gov/41508136/). *Hum Genomics*. [Basic Science / Preclinical]
Takenaka R (2026). [PMID: 41407872](https://pubmed.ncbi.nlm.nih.gov/41407872/). *Skeletal Radiol*. [Review / Meta-Analysis]
Çapkan DÜ (2026). [PMID: 41616580](https://pubmed.ncbi.nlm.nih.gov/41616580/). *Thromb Res*. [Other]
Warren BB (2026). [PMID: 41979075](https://pubmed.ncbi.nlm.nih.gov/41979075/). *Haemophilia*. [Epidemiology / Natural History]
Polack B (2026). [PMID: 41870437](https://pubmed.ncbi.nlm.nih.gov/41870437/). *J Comp Eff Res*. [Epidemiology / Natural History]
Matino D (2026). [PMID: 41351884](https://pubmed.ncbi.nlm.nih.gov/41351884/). *Blood*. [Clinical Trial Publication]
Seeliger A (2025). [PMID: 41675632](https://pubmed.ncbi.nlm.nih.gov/41675632/). *Front Med (Lausanne)*. [Basic Science / Preclinical]
Siddiqui E (2025). [PMID: 40368339](https://pubmed.ncbi.nlm.nih.gov/40368339/). *Clin Appl Thromb Hemost*. [Review / Meta-Analysis]
Gaviappa D (2025). [PMID: 40417435](https://pubmed.ncbi.nlm.nih.gov/40417435/). *Int J Clin Pediatr Dent*. [Case Report / Case Series]
AI-curated news mentioning mild hemophilia B
Updated Sep 8, 2026
A study evaluates the completeness of a medical record dataset linked to administrative claims for patients with hemophilia B. This research highlights the potential of tokenization in improving data accuracy and accessibility for rare disease management.
A study highlights the use of antibiotic lock therapy for salvaging central venous ports infected with Pseudoxanthomonas in a child with hemophilia B. This approach may offer insights into managing infections in pediatric patients with rare diseases.
Research highlights the discovery and optimization of marstacimab, a human monoclonal antibody designed to target tissue factor pathway inhibitor for treating hemophilia A and B. This advancement could lead to new therapeutic options for patients with these bleeding disorders.
Gene therapies are priced between $2.1M and $4.25M, creating significant access barriers for families affected by rare diseases. Notable therapies include Hemgenix for hemophilia B at $3.5M and Lyfgenia for sickle cell disease at $3.1M, raising concerns about insurance coverage and Medicaid gaps.